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StllTullary 
Freshly isolated lymph node (LN) cells cultured in serum-containing medium were restricted 
to produce primarily interleukin 2 (II:2) subsequent to T cell activation. Only minimal amounts 
of I1:4, I1:5, or interferon "y (IFN-3,) were produced under these conditions. Similar populations 
of LN cells cultured in serum-free medium were able to produce a variety of lymphokines after 
T cell activation, with the relative quantities of each species being dependent upon the lymphoid 
organ source of the lymphocytes. A similar relationship in the patterns of lymphokines produced 
by activated T cell hybridomas maintained under serum-free conditions was also observed, whereas 
activation in serum-supplemented media resulted in a predominant restriction to the secretion 
of I1:2. Additional studies determined that the entity in serum responsible for restricting T cell 
function in vitro was platelet-derived growth factor (PDGF). The PDGF-BB isoform was established 
to be the most active in the regulation of T cell function, enhancing IL-2 while depressing the 
production of I1:4, I1:5, and IFN-'y at concentrations below 1 ng/ml. PDGF-AB was also found 
to be quite active, however, this isoform of PDGF was incapable of influencing IFN-3' production 
at the concentrations tested. PDGF-AA was very weakly active. It therefore appears that PDGF, 
acting primarily through a fl receptor subunit (either odfl- or ~/~-type receptors)  is able to 
influence profoundly the behavior of T  cells, with some of its modulatory effects exhibiting 
isoform specificity. This is reflected by an enhancement in the production of I1:2, while simul- 
taneously depressing the secretion of I1:4, I1:5, and IFN-v (PDGF-BB only) after T cell activation. 
Kinetic studies, where cell supernatants were analyzed both 24 and 48 h after T cell activation, 
suggested that "desensitization" to PDGF influences can occur naturally in vitro. Those species 
of lymphokines that were inhibited by PDGF over the first 24 h after activation could be produced 
at normal levels over the subsequent 24-h period. Finally, lymphokines maintained in the presence 
of PDGF-BB for greater than 24 h before their activation lost sensitivity to this growth factor. 
These cells regained responsiveness to PDGF after an additional incubation period in PDGF-free 
medium. Collectively,  our data imply that the pattern of T  cell lymphokines produced, plus 
the kinetics of their production after activation, are being controlled by the potent serum growth 
factor PDGF. These original observations have important implications to our understanding of 
T cell function under normal, altered,  or pathologic conditions. Our data indicate that serum- 
supplemented  culture medium, or any procedure where an exogenous source of PDGF is present, 
will significantly influence T cell behavior. These effects need to be considered when interpreting 
the results of experiments conducted in vitro. 
N 
'o cell lives in an environment that is isolated from sub- 
stances capable of modifying  its behavior. Consequently, 
to fully understand the changes in growth, differentiation, 
and metabolism, which result from a cell's encounter with 
a defined stimulus, requires consideration of all factors that 
are influencing the cell, at or near the time of its stimulation. 
Mature T cells are not exempt from these basic rules of cell 
biology since the nature of their behavior, subsequent to an- 
tigenic stimulation, can be controlled by a variety of exoge- 
nous influences. These include the arachidonic acid metabo- 
lites (1, 2), steroid and polypeptide hormones (3-7), plus any 
other substances or physical properties able to quantitatively 
or qualitatively  alter cellular responsiveness (e.g.,  tempera- 
ture, available nutrients, etc.). 
Much of our present knowledge about T cells and the mech- 
anisms that govern their behavior has evolved from studies 
conducted in vitro. Differences among the responses elicited 
by cells that are isolated from a particular lymphoid tissue 
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absence of a given stimulant, are taken to represent the in- 
herent responsiveness of  the T cell. The failure ofT cells within 
the unstimulated "control" population to express a partic- 
ular response  is generally considered to reflect the absence 
of any inherent changes within these cells on the genes or 
gene products encoding or controlling that response. 
The complexity of regulatory control that exists over most 
cellular genes, with numerous individual influences  able to 
alter such events  as the rate and duration of transcription, 
translation,  posttranslational modifications, and  secretory 
processes, indicates that it may be unrealistic not to consider 
that some relevant  influences  are being exerted on popula- 
tions of T cells taken from in vivo lymphoid tissue environ- 
ments and placed in vitro. The presence of these influences 
might only  become evident after T cell activation, since stim- 
ulation may be necessary to elicit the desired changes in cel- 
lular behavior. A simple example of this concept can be dem- 
onstrated by  the  depressive  influences  on  Ib2  or  IFN-3/ 
production on resting T  cells exposed to either glucocorti- 
colds  (GCS)  or  PGE2 (1-4).  Cellular  activation must be 
achieved before the regulatory influences by these agents on 
the programming of T cell behavior are fully realized. There- 
fore,  to appreciate  the myriad of immunobiologic changes 
which accompany aging (8, 9), stress (10, 11), trauma (12-14), 
or even the maturation of immunologic responses in normal 
animals (15-17),  requires  that the experimental systems em- 
ployed are not themselves  altering cellular behavior in ways 
that might lead to erroneous conclusions. 
Our research efforts have recently been focused on the na- 
ture, types, and biologic consequences  that follow a T cell's 
encounter with natural endogenously produced steroid hor- 
mones (4, 5, 18). We have been able to demonstrate that many 
types of natural steroid hormones are able to alter T cell be- 
havior in definable, hormone-specific manners by employing 
serum-free systems in vitro (18). We now report that the use 
of serum-supplemented medium restricts activated T cells to 
predominantly produce Ib2 after activation. The causative 
factor in serum was established to be platelet-derived growth 
factor (PDGF), 1 which is abundantly present in virtually all 
sources of serum. PDGF is not normally present in the lym- 
phoid organ microenvironments where most T cells reside. 
Instead, PDGF represents a molecule that is primarily restricted 
in its action to paracrine pathways and exists in abundance 
at tissue sites of inflammation or injury where platelets are 
being activated.  A number of the more important implica- 
tions of our findings are discussed. 
Materials and Methods 
Mice 
Male and female C57BL/6 strain mice were bred and housed 
in the Laboratory Animal Facility at the University of Utah from 
breeding stock originally purchased from the National Cancer In- 
1Abbreviation used in this paper: PDGF, platelet-derived  growth factor. 
stitute. Mature adult mice of both sexes were used as LN donors 
and ranged in age from 12 to 20 wk. In any given experiment, 
pools of  peripheral LN (axillary,  brachial, and inguinal) from three 
to five mice (age and sex matched) were pooled. The animal fa- 
cility at the University of Utah guarantees strict compliance  with 
regulations established by the Animal Welfare Act. 
Reagents 
Antibodies.  The mAb reagents used in the present study were 
obtained from a variety of sources. The anti-IIr  ($4B6), anti-IIr 
(11Bll), anti-IFN-3/(XMG1.2 and R46A2), and anti-Ib5 (TRFK4 
and TRFKS)-producing hybridomas  were obtained from either the 
American Type Culture Collection (R.ockville, MD), or as gifts 
from Dr. T. Mossman and Dr. R. Coffman (DNAX,  Palo Alto, 
CA). The cell line producing the hamster anti-murine CD3e mAb 
145.2C was obtained from Dr. J. Bluestone  (University of  Chicago, 
Chicago, IL). Each of the cell lines was adapted to growth under 
serum-free conditions (see culture conditions) to facilitate  antibody 
purification from cell supernatants. The anti-II~4 mAbs (BVD4- 
1Dll and BVD6-2462) were obtained  from PharMingen  (San Diego, 
CA). 
Bioactive Compounds.  Murine  rlI~2 and rlL-4 were obtained  from 
Collaborative Biomedical Products, Inc. (Bedford, MA). Murine 
rlFN-'y was obtained from Genentech (San Francisco, CA), and 
murine rlL-5 was a gift from Dr. Robert Coffman (DNAX). These 
reagents were used as reference standards in the bioassays for IL-2, 
or in the capture ELISAs  used to quantitate the other lymphokines. 
Human rPDGF-AA, PDGF-AB,  and PDGF-BB  were obtained from 
Boehringer Mannheim Corp., (Indianapolis, IN). 
Culture  Conditions 
Routinely, single  cell suspensions of  LN cells were prepared from 
a group of normal mice, washed twice in sterile balanced salt solu- 
tion, and resuspended at a density of 10  v  cells/ml in a 24--well plate 
(Falcon Plastics, Baxter Scientific  Products, Sunnyvale,  CA). Cul- 
ture medium consisted of RPMI  1640 supplemented with 1% 
Nutridoma-SR (Boehringer Mannheim Corp.) antibiotics, 2 mM 
L-glutamine, and 5 x  10 -s M 2-ME. In some experiments, 10% 
FCS or PDGF-depleted FCS (Hyclone Laboratories, Logan, UT) 
was used in place of the Nutridoma supplement. Lymphocytes  were 
activated by the addition of I/lg/ml anti-CD3e and supernatants 
collected after 24 h or when indicated. Cultures were incubated 
at 37~  in a 10% humidified incubator. Preliminary studies have 
indicated the cell density, incubation periods, and anti-CD3e con- 
centration  to  be  optimum  for  lymphokine  production  using 
Nutridoma-supplemented  medium. Culture supernatants  were har- 
vested, clarified  by centrifugation, and stored at 4~  until assayed 
for specific lymphokine content. 
Preparation and Stimulation  of T  Cell Hybridomas 
The method of Kappler et al. (19) was used to construct a panel 
of antigen-specific  T cell hybridomas. All established clones have 
been recloned or retested for their capacity to produce II~2, II~4, 
and II.-5 after appropriate activation. Each of the hybridomas used 
in this study produce consistent  patterns of these lymphokines  when 
stimulated  with  soluble anti-CD3e  plus  accessory cells (e.g., 
LB15.13), or when cultured on 24-well plates containing immobi- 
lized anti-CD3e. Immobilized anti-CD3e plates were prepared by 
placing 250 #1 of a 1-~g/ml solution of anti-CD3E in 0.01 M Tris- 
HC1 (pH 9.6) into each well of a 24-well plate for 24 h at 4~ 
followed  by extensive  washing with sterile balanced salt solution. 
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11.,2.  The  lymphokine-dependent  cell  line,  HT-2,  has  been 
adapted to grow under serum-free conditions (RPMI 1640 +  1% 
Nutridoma SR) in the presence of 20 U/ml ofrlL-2. Murine rib2 
used for propagation of HT-2 was derived from culture superna- 
tants of X6AgS-653 cells (received from F. Melchers,  Basel Insti- 
tute Immunology, Basel, Switzerland) that had been transfected 
previously with multiple copies of the murine Ib2 gene (20). This 
cell line has also been adapted to growth under serum-free  condi- 
tions. We have modified the bioassay of  Hansen et al. (21) to utilize 
HT-2 as an indicator cell line to determine the relative titer of IL-2 
produced by activated  T ceils. Each test  supernatant was titrated 
in duplicate  into serum-free  medium against a constant number 
of HT-2 and a constant amount of anti-II.,4 (11Bll).  During the 
final 4 h of a 24-h incubation period, 5 #g of  2-[4,5-dimethylthiazole- 
2-yl]-2,5 diphenyl tetrazolium bromide (MTT) was added to each 
culture. After the 4-h period, 100/A of  a 20% SDS/50% dimethyl- 
formamide solution was added to each culture well. Spectrophoto- 
metric  readings  at  570-650 nm were  made on  a  Vm,~ 96-well 
microtest plate spectrophotometer  (Molecular Devices Corp., Menlo 
Park, CA). One unit of Ib2 in a test supernatant was equivalent 
to the optical density of a half-maximal response  to the standard 
rIL-2. 
CaptureELISAsforlL4, 11.5, andlFN-%  IL-4,  IL-5, and IFN-y 
levels in test supernatants were quantitatively measured by specific 
ELISA according to modifications of the method of Schumacher 
et al. (22). Briefly, a purified  population of antilymphokine mAb 
(anti-IL-4,  anti-IL,5,  or anti-IFN-30 was adsorbed  to 96-well cul- 
ture wells at a concentration of 2/~g/ml in 0.05 M Tris-HCl (pH 
9.6). Various amounts oflymphokine reference standards of  known 
biologic activity, or dilutions of test supernatants,  were dispensed 
into wells containing the specific capture antibody. After a 90-min 
incubation at 37~  all wells were washed carefully  with 0.05% 
Tween-20 in PBS. The second antilymphokine antibody, which was 
biotinylated, was then added,  incubated for 90 min at 37"C, and 
given another extensive washing in Tween-PBS. Avidin-horseradish 
peroxidase treatment, followed by the addition of ABTS-substrate, 
was used to develop the ELISA. Optimal density readings  at 405 
nm were taken using a Vm,* 96-well microtest plate spectrophoto- 
meter.  Our limit of detection for II.-4 is 15-30 pg/ml, for IL-5 is 
30 pg/ml, and for IFNw 30-60 pg/ml. The capture ELISA method 
has proven to correlate  quite closely with standard  bioassays for 
detection of the same lymphokines. 
Results 
Serum Effects on  Lympkokine  Production by Activated  T 
Cells.  Lymphocytes  were collected from nonmucosal LN (ax- 
i11ary, brachial, and inguinal), mucosal  LN  (deep cervical, 
parathymic, and periaortic), and spleen of normal C57BL/6 
strain mice. These three populations  of lymphoid cells were 
then prepared for in vitro culture under serum-flee and serum- 
containing conditions (10% FCS),  and stimulated with an 
optimum amount of anti-CD3e. 24 h later, culture superna- 
tants were collected and quantitatively analyzed for the pres- 
ence of Ib2,  Ib4,  Ib5,  and IFN-%  The results presented 
in Fig.  1, A-D indicate  that  the patterns of lymphokine 
production are quite different between activated T cells stimu- 
lated under serum-free and those  stimulated  under serum- 
containing conditions.  The presence of FCS augmented the 
amount of I1,2 produced by T ceUs from all three lymphoid 
compartments (Fig. 1 A), while simultaneously reducing the 
production  of Ib4 (Fig.  1 B), IL-5 (Fig.  1 C), and IFN-q, 
(Fig.  1 D). 
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Figure  1.  T  cells activated in 
vitro  produce different  patterns 
of  lymphokines  when  activated 
under serum-flee or serum-contain- 
ing conditions. Lymphocytes  were 
obtained from nonmucosal  LN (axil- 
lary, brachial, and inguinal) (I), 
mucosal LN (parathymic, periaortic, 
and deep cervical) (1~), and spleens 
([])  of normal  C57BL/6  strain 
mice. 107 cells/ml were cultured in 
the absence (1% Nutridoma SR) or 
presence of 10% FCS with the ad- 
dition of an optimum amount of 
soluble anti-CD3e (1.5/zg/ml). Su- 
pernatants were collected  after 24 h 
and quantitatively analyzed for the 
described lymphokines. Unstimu- 
lated control cultures, in the pres- 
ence or absence of serum, were un- 
able to produce detectable levels of 
the lymphokines  tested. This experi- 
￿9  ment has been repeated four times 
with  similar results. 
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also  affect lymphokine production by homogenous T  cell 
populations, we analyzed lymphokine synthesis by a number 
of T cell hybridomas. All of our T cell hybridomas have been 
adapted to grow under serum-free conditions (1% Nutridoma 
SR), thereby allowing us to maintain them without any pos- 
sible serum-mediated influences. When activated in vitro with 
soluble anti-CD3e, in the presence of an accessory cell source 
(LB15.13),  each T  cell hybridoma produces a characteristic 
and reproducible pattern of the lymphokines Ib2 and II.-4. 
We found that T cell hybridomas, similar to freshly isolated 
lymphocytes, produced different amounts of 1I.-2 and II.-4 
after activation under serum-free and serum-containing con- 
ditions. A representative example is provided in Fig. 2 that 
dearly demonstrates that the inclusion of 10% FCS in the 
culture medium enhanced Ib2 production while simultane- 
ously inhibiting the production of IL-4. Identical changes in 
the pattern of IL-2 and IL-4 production are consistently ob- 
served with all of the T cell hybridomas tested (n -- 4, data 
not shown). These experiments have been repeated numerous 
times with similar results. The very dear distinctions in the 
patterns of lymphokines produced by T cells residing within 
mucosal or nonmucosal lymphoid organs of  normal mice when 
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T cell hybridomas stimulated under serum-free  or serum- 
containing  conditions  respond  differently  to stimulation  with anti-CD3e. 
The T cell hybridoma  HBD13.2 has been adapted to grow in serum-free 
medium (see  Materials and Methods). Hybridoma  cells (5 x 10Uml)  were 
cultured in the presence  or absence  of 10% FCS with 2 x 10S/ml  LB15.13 
as a source  of accessory  cells. Parallel  sets of  cultures  were  stimulated  with 
1/~g/ml anti-CD3e  and the supernatants  collected  and analyzed  after  24 h. 
Both II--2  and Ib4 productions  were  quantitated  by the procedure  described 
in Materials and Methods. Unstimulated  T cell bybridomas  in the pres- 
ence of LB15.13 produce  undetectable  levels of the tymphokines  tested. 
stimulated under serum-free  conditions is quite consistent with 
our previously published findings (23),  while the patterns 
of lymphokines produced by T cells stimulated under serum- 
containing conditions (a predominance of I1.-2 with minimal 
production of the other lymphokines) is similar to the pub- 
lished reports by other investigators (15-17,  24). 
A significant emphasis has recently been placed on the value 
of quantifying the potential of T cells to produce lymphokines 
through an assessment of the patterns of these secreted prod- 
ucts found in cell supernatants after T  cell activation. Be- 
cause of the very well-described activities of individual lym- 
phokine species, quantitative and kinetic assessments of their 
production have been used as indicators of host immunocom- 
petence (25-27), the effects of drug therapies (1, 3,  11), and 
the maturational status of the immune system of naive animals 
(15-17, 24, 28, 29). An accurate reflection of the in situ con- 
ditions is therefore quite important. 
Serum contains a number of substances that are not gener- 
ally part of a normal T cell microenvironment when residing 
within a lymphoid organ. Most notable are the many potent 
growth factors normally sequestered within blood platelets 
that are released as a consequence of dot formation. These 
include PDGF, transforming growth factor c~ (TGF-o  0, and 
transforming growth factor/3 (TGF-3). With the exception 
of TGF-3, which is known to be quite immunosuppressive 
(30, 31), the role(s) played by other platelet-derived substances 
on the behavior of T  cells has not been characterized. 
PDGF Regulates Lymphocyte Function.  Based on the re- 
cent report that documented the existence of PDGF receptors 
on human T cells (32), we were led to question whether serum 
PDGF was responsible for the observed influences on T cell 
behavior in vitro. T-cell hybridoma cell lines were propagated 
under serum-free conditions and cultured in the presence of 
medium supplemented with 10% FCS, 10% PDGF-depleted 
FCS, 1% Nutridoma SR, or 1% Nutridoma SR plus 1 ng/ml 
PDGF-AB. All cultures were stimulated with an optimum 
amount of immobilized anti-CD3e and supernatants collected 
for lymphokine analysis 24 h later. The results of this experi- 
ment (Fig. 3) demonstrate that PDGF can significantly alter 
lymphokine production by activated T  cells. Similar to the 
changes observed with serum, T cells placed into PDGF-AB- 
supplemented medium produced enhanced levels of II.-2 (Fig. 
3 A), and were almost totally inhibited in their production 
of IL-4 and Ib5 (Fig. 3, B and C). Although some additional 
undefined factors may have also been removed, supplementa- 
tion of the T cell hybridoma growth medium with PDGF- 
depleted FCS resulted in responses quite similar to those ob- 
tained under serum-free conditions. Therefore, PDGF appears 
to provide a major influence on T cell function, simultane- 
ously enhancing the production of certain T cell lymphokines 
(IL-2) while profoundly inhibiting the production of others 
(e.g., II-4 and IL-5). 
PDGF Influences on  T  Cells Is Mediated through a B-type 
Suhunit Receptor.  PDGF is known to be encoded by sepa- 
rate genes for two possible subunit chains (A chain and B 
chain) which can form three possible dimers (AA, AB, and 
BB) (33-37). Competition studies have recently determined 
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Figure 3.  PDGF appears to be responsible  for the restriction in lym- 
phokine production by T cells  cultured in serum-containing  medium. The 
HBD13.2 T cell hybridoma was propagated in serum-free  medium. Ali- 
quots of these cells (5  ￿  105/ml)  were placed in medium containing the 
supplements described  and immediately  added to culture plates containing 
immobilized anti-CD3e. Superuatants were collected after 24 h and ana- 
lyzed quantitatively for I1:2 (A), II:4 (B), and I1:5 (C) (Methods). Con- 
trol values  were below the level  of  detection in our assays. This experiment 
has been repeated five times on many T cell hybridomas. 
that different isoforms of PDGF bind to distinct  classes of 
PDGF  receptors (36).  Present  evidence indicates  that  high 
affinity binding  of PDGF  requires  the  association  of two 
different receptor subunits: an ot subunit that can efficiently 
bind to either A  or B chains,  and a 13 subunit that can bind 
only a B chain. Therefore, PDGF-AA is restricted to binding 
odoz receptors only, PDGF-AB binds to both oz/c~ and oz//3 
type receptors, while PDGF-BB can form high affinity com- 
plexes with either oz/o~, &B, or/3//3 type receptors (33, 36). 
We questioned whether PDGF-mediated alterations to T 
cell  function  were restricted  to  particular  types  of PDGF 
receptors. T  cell hybridomas maintained in serum-free medium 
were stimulated  with immobilized anti-CD3e  in the pres- 
ence  or  absence  of various  amounts  of added  PDGF-AA, 
PDGF-AB, or PDGF-BB. Results of the analysis on their ability 
to produce lymphokines (Fig. 4) demonstrated that PDGF- 
AA  was  ineffective, while  PDGF-AB  and  PDGF-BB  were 
highly effective at altering the production of Ib2,  IL-4, and 
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Figure 4.  The PDGF influences  on T cell function are dose dependent 
and appear to be mediated through a B-type receptor subunit. The T cell 
hybridoma T68.2 was placed  into culture at 5 x  105 cells/weU  in the pres- 
ence of the specified  amounts of human rPDGF-BB,  PDGF-AB, or PDGF- 
AA, and stimulated with immobilized  anti-CD3e. Supernatants were col- 
lected after 24 h and assayed for the presence of I1:2 (A), ID4 (/3), and 
I1:5 (C). Control values were below detectable limits. This experiment 
has been repeated two additional times with different T cell hybridomas. 
The levels of each lymphokine produced by activated T cell hybridomas 
in the absence of PDGF  _+  SEM are provided in the bars at the right 
of each figure. 
IL-5 by activated T  cells at most concentrations tested (0.1-5 
ng/ml).  The use of immobilized anti-CD3e  eliminated the 
need for accessory cell addition to the culture system, allowing 
us  to  determine  that  the  PDGF-mediated  influences  were 
directly related  to T  cell effects. Similar findings  were ob- 
tained when freshly isolated lymphocytes from peripheral LN 
were  used  in  a  parallel  analysis  (Fig.  5).  Finding  that  the 
production of IFN-3, by activated T  cells was inhibitable by 
PDGF-BB at low concentrations, but by PDGF-AB only at 
1327  Daynes  et al. the highest concentration tested, was unexpected. Presently, 
we have no explanation for this finding, but it may relate 
to differential receptor subunit expression on T cell subsets. 
Our results suggest that both the stimulatory effects of PDGF 
(AB and BB) on I1:2 production and the inhibitory effects 
on II:4, I1:5, and IFN-'y (BB only) production by the growth 
hormone appear to require a/3 subunit of the PDGF receptor 
being present on the responsive T  cells. 
PDGF Differentially Affects the Kinetics of Lymphokine Produc- 
tion by Activated T Cells.  Freshly isolated peripheral LN lym- 
phocytes were cultured in serum-free medium in the pres- 
ence or absence of 10% FCS, 1 ng/ml of PDGF-BB,  or 2.5 
ng/ml of PDGF-AB.  Cell cultures were stimulated by the 
addition of anti-CD3e, and supernatants collected at 24 and 
48 h for quantitative lymphokine analysis. The results (Fig. 
6, A-D) indicate that maximal levels of I1:2, I1:4, I1:5, and 
IFN-'y are achieved by 24 h when lymphocytes are activated 
under serum-free conditions, and these levels change minimally 
over the second 24-h period. T cells cultured in the presence 
of serum or PDGF (BB or AB) demonstrated similar kinetics 
for I1:2 production, with maximal levels achieved by 24 h. 
Conversely, very little IL-4, I1:5, and IFN-'y were produced 
by T  cells activated in the presence of serum of PDGF-BB 
over the initial 24-h period. After 24 h in culture, however, 
significant I1:4, II--5, and IFN-~' production were observed 
over the second 24-h period in culture. Once again, PDGF- 
AB, while being stimulatory to I1:2 and inhibitory to I1:4 
and I1:5, had no effect on the production of IFN-3,. Down- 
regulation of IFN-3' production therefore appeared to be re- 
stricted to PDGF-BB only. The results  of this experiment 
suggest that cellular adaption (or desensitization) to the effects 
of PDGF are taking place over the initial 24-h period, and 
further suggest that the regulatory effects by this growth hor- 
mone are transitory in nature. 
Our findings suggested that PDGF-responsive T cells, placed 
into a PDGF-rich microenvironment (AB or BB), initially 
possess but then lose their sensitivity to this growth factor. 
We tested this directly by employing T cell hybridomas that 
had previously been adapted to in vitro growth under serum- 
free conditions. The results of this study are presented in Fig. 
7. As previously demonstrated, T cell hybridomas maintained 
in serum-free medium were highly responsive to the effects 
of both PDGF-AB and PDGF-BB,  as evidenced by an en- 
hancement in I1:2 production and a marked depression in 
the levels of I1:4 and IL-5 when activated with immobilized 
anti-CD3e. Parallel cultures were maintained in the presence 
of 10 ng/ml PDGF-BB for a 48-h period. These cells were 
then washed free of growth hormone and activated with im- 
mobilized anti-CD3e in the presence or absence of freshly 
added PDGF-AB (2.5 ng/ml) or -BB (0.5 ng/ml). The results 
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Figure 5.  Dose-response  effects 
of PDGF on murine LN T cells. Pe- 
ripheral  LN were  harvested  from 
C57BL/6 mice and prepared for cul- 
ture in serum-free medium at a con- 
centration of 107 ceUs/ml. 1-ml cul- 
tures  were established  in  24-well 
plates.  Each  of  the  isoforms  of 
PDGF (AA, AB, BB) was added to 
duplicate wells at the indicated con- 
centrations.  The T cells were acti- 
vated by the addition  of 1 #g/ml 
anti-CD3e.  Culture  supernatants 
were harvested after 24 h and quan- 
titativdy assayed for IL-2, IL-4, IL-5, 
and IFN-% Unstimuhted, normal, 
and PDGF-only controls produced 
lymphokines below the level of de- 
tection in our assays. This experi- 
ment has been repeated twice. Posi- 
tive control (minus  PDGF) values 
for each lymphokine  +  SEM are 
provided in the bars to the fight of 
each figure. 
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Figure  6.  Kinetic analysis of 
lymphocytes  production by murine 
peripheral LN cells in the presence 
or absence of PDGF-BB, -AB, or 
serum. Peripheral LN cells from 
C57BL/6 mice were prepared for 
culture at 107 cens/ml under serum- 
free conditions. To parallel culture 
wells,  2.5  ng/ml  PDGF-AB,  1 
ng/ml PDGF-BB, or 10% FCS were 
added just before activation with 
1/zg/ml anti-CD3e. Positive con- 
trols consisted of cells activated 
without ~dd~ supplements. All cul- 
tures were activated  by the addition 
of 1/~g/ml anti-CD3e and super- 
natants from duplicate  wells  for each 
condition were harvested after 24 
and 48 h. IL-2, IL-4, IL-5, and IFN~ 
levels  were quantitated as described 
in  Materials and  Methods. Un- 
stimulated  control values were 
bdow detectable  limits and this ex- 
periment has been repeated twice 
with similar results. 
demonstrated that PDGF-adapted cells became refractory to 
the regulatory influences of this growth factor as a conse- 
quence of being maintained  in PDGF-containing  medium￿9 
We have repeated this type of experiment many times, em- 
ploying either PDGF or 10% FCS in the adaption culture 
system. The results were always identical to those presented 
above (data not  shown)￿9 
Many cell types are rendered nonresponsive to the modula- 
tory influences of specific  polypeptide hormones by main- 
taining them in their physical presence. This process is termed 
"desensitization;' "downregulation" or "adaption" and is often 
accompanied by a reduction in the number of membrane- 
associated  hormone  receptors.  Cellular  desensitization  to 
PDGF is a well-described phenomenon in numerous cell types, 
is associated with a loss in surface receptor presence (38), and 
should be reversible when PDGF-desensitized cells are sub- 
sequently maintained  under  hormone-free  conditions.  We 
therefore questioned whether PDGF-desensitized T cell hy- 
bridomas could reacquire sensitivity to this growth factor. 
T  cell hybridomas, desensitized to the influences of PDGF 
by a 48-h culture period in its presence (10 ng/ml of PDGF- 
BB), were subsequently incubated under PDGF-free condi- 
tions for a 24-h period. These cells were then activated by 
immobilized anti-CD3e in the presence or absence of added 
PDGF-AB or -BB.  The results (Fig.  7, A-C) demonstrate 
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that desensitized T cells can reacquire sensitivity to both iso- 
forms of PDGF after maintenance under PDGF-free condi- 
tions.  Once, again,  PDGF-AB and PDGF-BB were able to 
enhance the ability of these activated cells to produce II.-2, 
while simultaneously depressing their production of Ib4 and 
IL-5. 
Discussion 
Our findings indicate that  serum,  specifically  the PDGF 
within serum, is able to exert significant influences on T cell 
behavior, which became evident subsequent to activation. T 
cells isolated from various lymphoid organ microenvironments, 
or T  cell hybridomas,  were found to respond quite differ- 
ently in vitro, when stimulated with soluble anti-CD3e under 
serum-free or -containing conditions.  T  cells stimulated in 
the presence of serum were quite restricted in the types of 
lymphokines they produced, with IL-2 representing the pre- 
dominant  species. T  cells stimulated under serum-free con- 
ditions, however, produced numerous species oflymphokines 
over the subsequent 24-h period, including Ib2, IL-4, Ib5, 
and IFN-3,. The primary factor in serum responsible for the 
observed restrictions in lymphokine production was deter- 
mined  to be PDGF,  a potent  peptide biological  response 
modifier that  previously has not been considered to be an A  Adaption protocol ~  ~ 
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Figure 7.  Lymphocytes cultured in PDGF 
lose sensitivity to this growth factor but re- 
gain responsiveness  after its removal.  The T 
cell hybtidoma, Hd13.2, was maintained under 
serum-free conditions. A fraction of these cells 
were cultured with 10 ng/ml  PDGF-BB  for 
48 h to achieve desensitization or adaption. At 
the end of the 48-h incubation period, both 
control and PDGF-treated cells were washed 
and resuspended at 5  x  10  s cells/ml in serum- 
free medium.  An additional  set of cells were 
treated with PDGF-BB for 48 h followed by 
an additional  24-h period in its absence.  The 
cells were activated  on plates containing im- 
mobilized anti-CD3e in the presence or absence 
of PDGF-AB (2.5 ng/ml) or PDGF-BB (0.5 
ng/ml). Supernatants were collected 24 h after 
activation and analyzed for levels of ID2, ID4, 
and  ID5. 
important part of a T cell's microenvironment at time of ac- 
tivation. 
PDGF actually represents a family of molecules that is com- 
posed of dimers of two chains (A and B chains).  The two 
chains share 60% sequence identity and can dimerize to form 
PDGF-AA, PDGF-AB, and PDGF-BB. Each of the three dimer 
forms has been identified in nature and all  are biologically 
active. The relative distribution of the three isoforms of PDGF 
varies greatly depending upon its cellular source of produc- 
tion, and probably relates  to a variation in rate of A  and B 
chain  synthesis  (39). 
PDGF is able to stimulate a variety of cellular responses, 
including mitogenesis, Ca  2 § mobilization,  actin reorganiza- 
tion, chemotaxis, phosphatidylinositol turnover, and stimu- 
lation of tyrosine-specific phosphorylation (reviewed in ref- 
erence 33). Responses are elicited after PDGF binding to high 
affinity receptors, which themselves form plasma membrane 
dimers in the presence of ligand and gain biologic  activity 
(36,  38).  Two types of receptor subunits, termed ot and/3, 
are known to exist on individual cells. These receptor subunits 
can form homodimers or heterodimers, both of which are 
biologically active.  The PDGF receptor-ligand system is fur- 
ther complicated by the findings that: (a) A chains can only 
interact with ol receptor subunits, while B chains are fully 
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(36, 38); (b) the types of responses elicited through different 
c~ and B receptor isoforms may be distinct (33); and (c) varia- 
tions in PDGF species and the relative proportion of either 
oe or ~ subunits of the PDGF receptor in the plasma mem- 
brane can vary significantly depending upon the cell type plus. 
secondary regulatory influences received by the cells (33, 40). 
Our findings (Fig. 4 and 5) strongly implicate the ~ subunit 
of the PDGF receptor as being necessary for altering the pat- 
tern of lymphokines produced by activated T cells. The ability 
of PDGF-AB and PDGF-BB to provoke the greatest responses 
suggests that most responding T cells must display both oe 
and ~  subunits of the PDGF receptor,  with the ~  subunit 
being necessary for modifying cellular behavior. 
Two very obvious implications of our findings become im- 
mediately apparent. The first is associated with the almost 
universal usage of serum-supplemented culture medium in 
studies designed to elucidate the temporal sequence of mo- 
lecular and biochemical events that follow T cell activation. 
Results derived from these types of studies have been inter- 
preted by many investigators to reflect the immunologic  com- 
petence of the lymphocyte donor under either normal or 
anomolous conditions (25-27).  It is therefore very impor- 
tant to identify as many of the insidious factors present in 
a given experimental protocol that might also influence lym- 
phocyte function and possibly contribute inaccurately to the 
interpretation of the data obtained. PDGF is a polypeptide 
hormone that contaminates all serum sources. In vivo, T cells 
would be most profoundly affected by PDGF influences when 
residing in areas of close proximity to sites of platelet aggre- 
gation and activation. Injury, inflammation, or infection, create 
unique in vitro microenvironments where transient PDGF- 
mediated effects on infiltrating lymphocytes might serve to 
promote the donal expansion of specific antigen-responsive 
T  cells. 
It recently has been reported that the maturation of cel- 
lular responses in vivo begins with the activation of T cells 
that are predominantly restricted to the production of Ib2 
when stimulated (15-17,  24, 28, 29).  With time, the acti- 
vated T cells are believed to "mature" evidenced by the gaining 
of a capacity to produce a number of other lymphokines in- 
cluding Ib4, IL-5, and IFN-3/(6, 15, 17, 24). Our findings 
suggest that, at the population level, T cells in vivo possess 
the inherent potential to produce numerous lymphokines, 
but project the Ib2-dominant phenotype as a direct conse- 
quence of being programmed by PDGF-induced influences 
after their transfer  from in vivo to an in vitro environment. 
The acquisition of an ability to produce a more diverse range 
of lymphokines, concluded by others to represent a normal 
consequence of lymphocyte maturation (6, 7, 24), may actu- 
ally be the result of cellular adaption (or desensitization) to 
PDGF-mediated influences. The results of our experiments 
are consistent with this latter interpretation (Figs. 6 and 7). 
It is very important clinically to accurately assess the im- 
munologic status of individuals (either experimental animals 
or humans) whose immune systems are believed to be altered 
as a consequence of stress, trauma, drug therapies, aging, neo- 
plasia, or challenge with particular infectious agents. Altera- 
tions in the patterns of lymphokines produced by T cells after 
their stimulation may serve as important indicators of a host's 
ability to mount protective or pathologic types of immuno- 
logic responses after antigenic challenge (11, 26, 27). An ac- 
curate assessment of the potential to produce the various spe- 
des oflymphokines, both at the quantitative and qualitative 
levels, is necessary to derive the greatest usefulness from this 
information. We believe that our study indicates that the use 
of serum-supplemented medium in performing such evalua- 
tions  places  restrictions  on  the  information that  can  be 
generated. 
Serum contains numerous components that are able to exert 
profound influences over cellular behavior. These include not 
only PDGF, but all of the other biologic response modifiers 
that are normally physically restricted from generalized cel- 
lular contact by their incapsulation within platelets. In addi- 
tion, the enzyme systems that are activated, and the numerous 
products produced as a consequence of blood clotting, also 
bear consideration. In hindsight, therefore,  it is not at all 
surprising that T cell responses elicited under serum-free and 
serum-containing conditions would be quite different. 
After appropriate types of stimulation, it is also possible 
for macrophages plus a number of other normal and neo- 
plastic cell types to produce PDGF (41). The isoforms of PDGF 
produced by these cell types, either constitutively or in response 
to an exogenous stimulus, can vary in cell- and influence- 
specific manners (33). It is therefore possible that the PDGF 
effects on T  cells are both dynamic and complex, and vary 
significantly  within distinct tissue microenvironments. 
We recently reported that exposure of T cells to glucocor- 
ticoids, either in vivo or in vitro, actually enhanced their ca- 
pacity, upon stimulation, to produce ID4 while depressing 
IL-2 and IFN-3, synthesis (4). This observation could not have 
been made in serum-containing medium, where the produc- 
tion of both ILo4 and IFN-3, is inhibited by PDGF effects. 
The use of a serum-free culture system has also allowed us 
to reproducibly observe differences in the patterns of lym- 
phokines produced by T cells taken from distinct lymphoid 
organs (23).  T  cells resident within lymphoid organs that 
receive their predominant drainage from nonmucosal tissues 
produce significant amounts of II~2 and IFN-3, following ac- 
tivation. T cells from mucosal lymphoid organs produce far 
more ID4 and IL-5 after activation, and less IL-2 and IFN-3, 
than T cells from nonmucosal lymphoid organs. Our present 
findings offer an explanation as to why these differences were 
not previously observed in the past (Fig. 1). The potent depres- 
sive effects of PDGF on Ib4, IL-5, and IFN-3, production 
would minimize any inherent differences that may actually 
exist in the potential ofT cells derived from the various lym- 
phoid organs to respond to stimulation. 
It is becoming quite clear that many substrates exist, with 
origins predominantly extrinsic to the T cell, that are able 
to greatly alter its cellular responses. These include the ster- 
oid hormones, with dehydroepiandrosterone (42), glucocor- 
ticoids (4), dihydrotestosterone (5), and 1,25-dihydroxy vitamin 
D3 (18), each being capable of mediating distinct regulatory 
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to influence cyclic nudeotide levels in T cells, are also impor- 
tant  regulators of T  cell function (1).  Our present finding 
that PDGF has profound influences over T cell behavior, cou- 
pled with its preexistence with blood platelets and its ability 
to be produced by numerous cell types, suggests an active 
participation by this growth hormone in the molecular mech- 
anisms that govern the development of immunologic responses. 
Lymphocytes and monocytes move freely between many 
distinct tissues as part of their roles in immune surveillance 
and effector function.  Unlike cells that  comprise the solid 
organ systems where microenvironmental influences are some- 
what stable, the circulating mononuclear lymphoid cells are 
constantly being subjected to changing influences during the 
recirculation process. For optimal function, therefore, these 
cells must have the flexibility to rapidly adapt in an appro- 
priate manner to a variety of distinct microenvironments. Fi- 
delity in this process is necessary to guide the development 
and differentiation  of appropriate effector responses after a 
lymphocyte's productive encounter with antigen within a par- 
ticular  tissue.  PDGF may play more than  one role in this 
process. By its apparent ability to limit lymphocyte produc- 
tion of lymphokines with differentiation functions while aug- 
menting the production of II.-2, PDGF might amplify im- 
mune responses by its transient ability to focus the behavior 
of lymphocytes towards cellular proliferation. Clonal expan- 
sion is known to represent an absolute requisite for immu- 
nity and immunologic memory. A large dilution effect must 
occur where antigen-primed T cells enter the blood after resi- 
dence, activation, and clonal expansion in a secondary lym- 
phoid organ environment.  For cellular immunity to occur, 
some of these antigen-specific T cells must selectively extrava- 
sate into inflammatory sites of infection and carry out their 
programmed functions. It is possible that PDGF influences, 
exerted locally, provide a means for additional donal expan- 
sion of those T cells able to successfully traverse between the 
lymphoid organ  and the site of infection. 
Finally,  it should be emphasized that  this represents the 
very first report  of a role for PDGF, beyond a suggestion 
for mitogenesis (32), in the regulation of functional roles played 
by T  cells in the immune system. Finding that PDGF pro- 
foundly influences the functional behavior of T  cells by al- 
tering their secretion of lymphokines,  suggests an intimate 
linkage between this potent growth factor and the complex 
regulatory events associated with lymphocyte differentiation 
and the development  of immunity. 
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